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Abstract
Background: Severe complicated intra-abdominal sepsis (SCIAS) has an increasing incidence with mortality rates over
80% in some settings. Mortality typically results from disruption of the gastrointestinal tract, progressive and self-
perpetuating bio-mediator generation, systemic inflammation, and multiple organ failure. Principles of treatment include
early antibiotic administration and operative source control. A further therapeutic option may be open abdomen (OA)
management with active negative peritoneal pressure therapy (ANPPT) to remove inflammatory ascites and ameliorate
the systemic damage from SCIAS. Although there is now a biologic rationale for such an intervention as well as non-
standardized and erratic clinical utilization, this remains a novel therapy with potential side effects and clinical equipoise.
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Methods: The Closed Or Open after Laparotomy (COOL) study will constitute a prospective randomized controlled trial
that will randomly allocate eligible surgical patients intra-operatively to either formal closure of the fascia or use of the
OA with application of an ANPTT dressing. Patients will be eligible if they have free uncontained intra-peritoneal
contamination and physiologic derangements exemplified by septic shock OR a Predisposition-Infection-Response-Organ
Dysfunction Score ≥ 3 or a World-Society-of-Emergency-Surgery-Sepsis-Severity-Score ≥ 8. The primary outcome will be
90-day survival. Secondary outcomes will be logistical, physiologic, safety, bio-mediators, microbiological, quality of life,
and health-care costs. Secondary outcomes will include days free of ICU, ventilation, renal replacement therapy, and
hospital at 30 days from the index laparotomy. Physiologic secondary outcomes will include changes in intensive care
unit illness severity scores after laparotomy. Bio-mediator outcomes for participating centers will involve measurement
of interleukin (IL)-6 and IL-10, procalcitonin, activated protein C (APC), high-mobility group box protein-1, complement
factors, and mitochondrial DNA. Economic outcomes will comprise standard costing for utilization of health-care
resources.
Discussion: Although facial closure after SCIAS is considered the current standard of care, many reports are suggesting
that OA management may improve outcomes in these patients. This trial will be powered to demonstrate a mortality
difference in this highly lethal and morbid condition to ensure critically ill patients are receiving the best care possible
and not being harmed by inappropriate therapies based on opinion only.
Trial registration: ClinicalTrials.gov, NCT03163095.
Keywords: Intra-peritoneal sepsis, Septic shock, Peritonitis, Open-abdomen, Multiple organ dysfunction, Laparotomy,
Randomized trial, Bio-mediators
Background
Sepsis is an ever-increasing cause of death worldwide [1, 2],
with a current incidence that is estimated at between 18 to
31 million cases worldwide per year [2–6]. Mortality
approaches 30–40% when shock is present [7–9], although
this may be 80% in the developing world [1].
Intra-abdominal sepsis (IAS) constitutes the second most
common form of sepsis, which may be particularly severe
because of the unique anatomic, physiologic, and microbio-
logic characteristics of the abdominal cavity and its con-
tained hollow viscera [10]. Thus, it has been reported that
hospital mortality is highest for patients who have
intra-abdominal infection secondary to ischemic bowel or
disseminated infection [11].
Severe complicated intra-abdominal sepsis (SCIAS)
encompasses the most challenging situation physicians
and surgeons encounter. IAS is defined as severe when
associated with organ dysfunction [8, 12–14] and as
complicated when the inflammation or contamination
spreads beyond a single organ, causing either localized
or diffuse peritonitis [12, 15]. SCIAS, typically resulting
from secondary peritonitis, may be distinguished from
other causes of severe sepsis through a requirement for
surgical abdominal exploration to surgically address the
disruption in the gastrointestinal (GI) tract.
Patients with SCIAS require early hemodynamic sup-
port, source control, and antimicrobial therapy [15].
However, despite advances in diagnosis, surgery, and
antimicrobial therapy, mortality rates associated with
complicated intra-abdominal infections and IAS remain
exceedingly high [14]. Even with prompt appropriate
therapy, SCIAS may progress to septic shock and mul-
tiple organ dysfunction, largely because of peritoneal
and systemic inflammation. There is great variability in
the human immune response to an infectious focus, and
some individuals greatly overreact to an inciting infec-
tion and produce a massive bio-mediator storm that
propagates multi-system organ failure and death whereas
other individuals have little or no response to the same
stimuli. The failure to obtain adequate source control is
often the driving cause of SCIAS and has been identified
as an independent predictor of mortality in those with
this condition [16].
In patients with SCIAS, relaparotomy is often
necessary to eliminate persistent peritonitis or new
infectious foci [17–19]. Differentiating “failed source
control” [20, 21] from a self-propagating bio-mediator
storm is often difficult or impossible without abdom-
inal re-exploration (relaparotomy). In those randomized
to expectant management after laparotomy for
intra-abdominal sepsis, 42% still required relaparotomy
for suspected or proven persistent peritonitis in a large
Dutch multicenter randomized controlled trial (RCT)
conducted by van Ruler and colleagues [17]. Interestingly,
in this study, 31% of these patients had a negative relapar-
otomy. The results of this seminal study, however, largely
concluded a previously long-standing debate concerning
two surgical approaches to ensuring source control in the
peritoneal cavity that of “laparotomy on demand” (LOD)
versus “planned re-laparotomy” (PRL) [17, 22, 23].
In a PRL strategy, re-laparotomy with fascial closure is
routinely performed every 36–48 h in order to inspect,
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drain, lavage, and apply any other required source con-
trol for the abdominal cavity until the intra-operative
findings are negative for peritonitis [17]. LOD offers re-
peat laparotomy only in those patients in whom the lack
of clinical improvement or even clinical deterioration
suggests that ongoing peritonitis results from either per-
sistent peritonitis or a new infectious focus [17]. The
relative merits of either approach were widely debated
for years, until the conclusion of the above RCT [17].
Although this trial noted no difference in mortality be-
tween the two methods, the LOD strategy reduced direct
medical costs by 23% [17].
The equivalence in outcomes, coupled with an appar-
ent cost savings, resulted in the generation of consensus
guidelines recommending that LOD after laparotomy for
SCIAS be adopted as the standard of care [24]. Upon
critical review, however, the mortality in this RCT of
severe secondary peritonitis well illustrates the devastat-
ing nature of this disease, noting the associated mortality
of approximately one third of all enrolled patients re-
gardless of treatment allocation. No matter which cohort
is considered, this dismal outcome demands for the
design of alternative approaches to manage SCIAS in an
attempt to save more lives.
At present, pharmacologic approaches are not the an-
swer. Despite the substantial improvement in supportive
critical care that has occurred over time, there has not
been seminal advances in addressing the central dysregu-
lated inflammation ultimately causing the organ damage
that kills or maims patients with severe sepsis. Attempts
to derive pharmacologic therapies for combating
post-infective inflammation have proved to be incredibly
expensive and frustrating, with hundreds of failed
anti-mediator trials having been conducted without evi-
dence of significantly improved patient outcomes [25, 26].
A critical nuance to consider in understanding surgical
source control is that the van Ruler RCT did not utilize
a contemporary “open abdomen” (OA) approach in
either arms and that the abdominal fascia was formally
closed in both. Increasingly, the OA is being recom-
mended as an attractive option to provide better control
of intraperitoneal contamination. Now, this approach is
perceived to be a safer option than in previous decades
due to the development of advanced temporary abdom-
inal closure (TAC) devices, that offer greater safety in
protecting the viscera, and their potentially profound
benefits in ameliorating the propagation of inflammatory
bio-mediators in SCIAS [27–29].
The use of the OA for non-trauma general surgery is
increasingly being reported in uncontrolled series as a
potentially beneficial option for patients with SCIAS
[12, 20, 21, 30–32]. The use of the OA in severe sepsis
may offer early identification and increased drainage of
any residual infection, control any persistent source of
infection, more effectively remove bio-mediator-rich peri-
toneal fluid, provide prophylaxis against development of
the abdominal compartment syndrome, and allow for the
safe deferral of gastrointestinal anastomoses and a safer
exit at the index operation [12]. Compared to trauma
patients, however, patients undergoing OA management
for intra-abdominal sepsis have a greater risk of OA com-
plications, including enteroatmospheric fistula (EAF) and
intra-abdominal abscess formation, and a lower rate of
primary fascial closure (i.e., fascia-to-fascia closure within
the index hospitalization) [12, 13, 33–35].
Although case series reporting the use of the OA after
non-trauma laparotomies have been reported, there are
no other contemporary randomized studies to address
this critical issue. There has only been one other RCT
conducted prior to 2006 that randomized patients to a
closed or open strategy, but the techniques of OA
management used were inadequate as management of
the OA has undergone dramatic improvements in
technology and technique in recent years. Robledo and
colleagues randomized patients with severe secondary
peritonitis to an open or closed strategy after laparot-
omy, using a non-absorbable polypropylene (Marlex™)
mesh in a interposed position between the open fascia,
thus exposing the underlying bowel to great risk of enter-
ocutaneous or enteroatmospheric fistula formation [36].
The study was stopped at the first interim analysis. Al-
though the mortality difference between the two groups
did not reach statistical significance, the risk of death was
higher with the OA, interposed non-absorbable polypro-
pylene mesh strategy [36].
Although RCT data comparing techniques are needed,
meta-analyses conducted by our group [37] and the
Amsterdam group [34] have concluded that negative
pressure wound therapy (NPWT) treatment appears to
potentially be the safest and most effective OA manage-
ment technique currently available. Newer commercial
active negative pressure peritoneal therapy (ANPPT)
systems now available for OA may reduce the risks of
enterocutaneous fistula and facilitate enhanced delivery
of negative peritoneal pressure to the peritoneal cavity
[24, 37, 38]. Animal studies [39] and in silica modeling
of these animal studies [40] have shown that ANNPT
provides a greater degree of negative pressure throughout
the peritoneum, which may reduce plasma bio-mediator
levels when compared to more passive peritoneal drain-
age. Systemic inflammation (TNF-α, IL-1β, IL-6) in one
study was significantly reduced in the ANPPT group and
was associated with significant improvement in intestine,
lung, kidney, and liver histopathology [39]. Although the
mortality rate in the NPPT was 17 versus 50% in the con-
trol group, this difference was not statistically significant
(p = 0.19), likely due to the smaller numbers. A larger pro-
spective, but non-randomized, multi-center cohort study
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in critically ill/injured patients requiring an OA enrolled
280 patients from 20 sites, in whom 168 underwent at
least 48 h of consistent OA therapy [28], and compared
ANPPT and a second type of TAC that provides poten-
tially less efficient peritoneal negative pressure. Although
bio-mediator levels were not measured in this trial, the
30-day all-cause mortality rate was 14% in those treated
with ANPPT and 50% in those with the less efficient nega-
tive pressure TAC [28].
Our research group has conducted the only prospect-
ive randomized controlled trial addressing this question,
the Intraperitoneal Vacuum Trial [27]. This RCT, con-
ducted in Calgary, Alberta, enrolled 45 out of 63 poten-
tially eligible patients over a 15-month period between
September 2011 and December 2012. Patients were en-
rolled in the operating room after an attending surgeon
made the decision that an abbreviated laparotomy was
required in critically ill/injured patients. In addition to
numerous physiological variables, bio-mediator levels
were measured every 24 h in the initial post-laparotomy
phase of critical care [27, 41]. Although standard sys-
temic bio-mediator levels were not statistically different
nor were peritoneal fluid drainage, the 90-day survival
rate was improved in the ANPPT group (hazard ratio,
0.32; 95% confidence interval, 0.11–0.93; P = 0.04) [27].
A valid critique of this trial was that despite the fact that
all patients were deemed to need OA therapy by the at-
tending surgeon, there was still a rather heterogeneous
mix of trauma and non-trauma patients [27]. Thus, al-
though unexplained, significantly improved survival with
ANPPT does warrant further exploration as a potential
treatment in patients affected by severe SCIAS. We
therefore believe that the global clinical equipoise as to
whether the abdomen should be left open or closed after
laparotomy in patients with SCIAS warrants a carefully
conducted multicenter RCT [30, 42].
Methods/design
Objective/aims
The aim of the study is to test the null hypothesis that
there will be no difference in survival when an OA
management strategy administering ANPPT is utilized
compared to a primary fascial closure strategy in pa-
tients with SCIAS. The study will be designed as a
prospective, single-blinded, multi-center, international
RCT. A SPIRIT diagram overview of the trial is pre-
sented in Table 1. The complete protocol is available at
https://coolstudy.ca/.
Setting
The study will be conducted in operating rooms around
the world where critically ill patients with SCIAS
undergo source control laparotomy. The lead study cen-
ter will be the Foothills Medical Centre, a Quaternary
Care Academic Medical Centre located in Calgary, Al-
berta, Canada. Other recruiting sites will be located in
developed countries around the world and will include
academic and community hospitals with the resources
necessary to participate in the trial and care for patients
with SCIAS during the entire clinical follow-up period.
Inclusion/exclusion criteria
Potential patients will first be identified in the emer-
gency departments, inpatient ward, and critical care
units of the participating centers. Eligibility will then be
confirmed in the operating room during the conduct
and near completion of a laparotomy for source control.
Patients will be eligible for inclusion if they have SCIAS,
as operationally defined by the COOL trial (Fig. 1).
The inclusion criteria are conceptually a two-part as-
sessment to ascertain if patients clearly fulfill the
definition of both severe and complicated IAS while
undergoing source control laparotomy. Thus, during the
laparotomy, it will become apparent to the operating
surgical team that the peritonitis is complicated,
which will be reproducibly demonstrated by uncon-
tained or unconfined purulent, feculent, or enteric
spillage. In addition to being complicated, the inclu-
sion criteria require that patients have severe IAS.
For the purpose of the COOL study, severe will be
defined by any of septic shock as defined by Sepsis 3
Consensus Guidelines [7], a World Society of
Emergency Surgery Sepsis Severity Score ≥ 8 [8], or a
Calgary Predisposition-Infection-Response-Organ Dys-
function Score ≥ 3 [43]. An elaborated explanation of
the thought processes and identification attributes of
these criteria modeled on a trial population of SCIAS
patients was previously published by the COOL inves-
tigators [44].
The qSOFA score was developed as a simple clinical
tool to identify patients with suspected infection who
were likely to have poor outcomes that did not rely on
laboratory testing [7]. However, during modeling, the
qSOFA actually had the lowest AUC of the systems for-
mally tested and a lower identification rates than the
other systems selected. This was consistent with other
opinions that the qSOFA might not be a sensitive
enough tool [45–48]. Therefore, although the qSOFA
score ≥ 2 is not an inclusion criterion, its ease of use on
the ward is attractive to serve as a flag for patients with
IAS in whom caregivers should assess further whether
critical features of SCIAS are present.
The exclusion criteria for COOL include (a) preg-
nancy, (b) perceived physical inability to physically close
the fascia primarily without undue tension or concerns
for inducing severe IAH/ACS, (c) intra-operatively deter-
mined absolute or imperative requirement for “damage
control” laparotomy including intra-peritoneal packing
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or non-anatomic post-surgical anatomy (i.e., surgically
placed permanent packing or bowel that the operating
surgeon believes must be left in discontinuity after resec-
tion), (d) the patient is expected to die shortly after
operation because of their condition in the operating
room and there is no intention of providing ongoing care
(i.e., the treating team wishes to close the abdomen to
leave the operating room with the sole intention of with-
drawing aggressive measures and providing only “comfort
care” in the ICU; an example of where this could occur
would be complete transmural midgut ischemia/necrosis),
(e) laparoscopic surgery (no laparotomy), (f) pancreatitis
as the source of peritonitis, (g) acute superior mesenteric ar-
tery occlusion as the primary pathology, (h) co-enrollment
in another investigational study, (i) peritoneal carcin-
omatosis, (j) traumatic injury within 24 h of the
development of SCIAS, (k) age < 18, or (l) uncon-
trolled bleeding. It will be important for surgeons
considering recruiting a patient to recognize before
enrolling and randomizing a patient that fascial clos-
ure is not possible, as recognizing this after allocation
to closure will constitute a protocol violation.
Table 1 SPIRIT diagram describing schedule of enrolment, interventions, and assessments [43]
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In current practice, it is likely that the most common
reason for non-eligibility will be a surgeon-based deci-
sion to resect a hollow viscus and due to the perceived
critical nature of the patient decision not to
re-anastomose the bowel but to instead perform damage
control and return the bowel ends into the peritoneal
cavity without a diverting stoma. As this is an absolute
indication for a future re-operation, these patients will
be ineligible for randomization. Although some authors
are critical of this practice [49], others recognize or even
recommend this approach [20, 30, 42, 49–51]. This
group of patients will be expected to constitute a signifi-
cant and important population of very sick patients who
although non-randomized and excluded constitute a
“defacto third arm” requiring follow-up and outcome
description.
Randomization
Treatment arm allocation will be randomly allocated
from a central, password protected, randomization web-
site (https://coolstudy.ca/). This will require an operating
room with access to the Internet, although accessing the
enrollment site needs not to be conducted by an actual
member of the surgical team. This site will be freely
open to the public; however, the ability to enroll a
patient can only be accessed with a password by any
member of the surgical/anesthesia/critical care medi-
cine/nursing team, thus freeing the senior surgeon to
concentrate on care. When an appropriate patient is rec-
ognized, the research website will be accessed, simple
identifiers of the patient will be entered, and treatment
allocation (CLOSED with fascial closure or OPEN with
an ANPPT TAC being applied) associated with this
entry will be generated. To ensure close balance of the
numbers in each of the two treatment groups, permuted
block randomization by site will be used. If the operating
team is uncertain regarding the potential stratified sever-
ity according to either the WSESSSS or CPIRO methods,
online decision support software will greatly simplify
these calculations regarding any potential enrollment.
Primary closure—CLOSED allocation
This strategy will consist of primary closure of the fascia
with placement of a closed-suction intra-peritoneal drain
(such as a Jackson-Pratt or Blake drain) to allow drain-
age of intra-peritoneal fluid for both clinical reasons and
to facilitate intra-peritoneal fluid testing. Closure of the
skin and the method for preventing surgical site infec-
tions will be left to the discretion of the attending
surgeon. There will be no formal requirement for rela-
parotomy. Post-operative diagnostic imaging and all
other aspects of post-operative care shall be at the
discretion of the treating critical care/surgical teams.
Any decision to perform a relaparotomy will be at the
discretion of the treating critical care/surgical teams,
and in no way mandated by this study, although this will
constitute a study outcome. If at any subsequent laparot-
omy, the attending and responsible surgeon selects an
open abdominal strategy as being in the patient’s best
interest, this will be permitted and the outcomes will be
analyzed considering the original intention to treat allo-
cation at enrollment. Any application of any wound suc-
tion or negative pressure device to the soft tissue above
the closed fascia will be permitted but will not change
the understanding that the fascia has been formally
closed and this is a patient with a closed abdomen.
Fig. 1 Inclusion criteria for COOL
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Open abdomen with active negative pressure peritoneal
therapy—OPEN allocation
The time that the TAC dressing will be left in place will
be left to the discretion of the attending surgeon, but
typical practice guidelines mandate either formal ab-
dominal closure or dressing changes at 24–72 h from
placement if it is not perceived that formal abdominal
closure can be completed [52] . For both arms of the
trial, it will be expected that attending surgeons are in-
volved in either the direct supervision or inter-operative
participation with either facial closure or temporary
abdominal closure in order to be an acceptable partici-
pating center. The trial is considered pragmatic in allow-
ing a variety of techniques as long as ANPPT is being
administered to an open peritoneal cavity defined by the
fascia not being formally closed and that all four
intra-peritoneal quadrants have been washed until
macroscopically clean [24]. Thus, any manner of
mechanical traction devices [53, 54], or potential in-
stillation therapies [55], will be permitted adjuncts as
long as the primary requirement for an open fascia
with ANPPT is met.
Clinical management protocols
After enrolment and allocation of abdominal compart-
ment management in the operating theater, all care will
be at the complete discretion of the clinical teams. If the
treating physicians decide that a CLOSED abdomen re-
quires re-opening, participation in the study will not in-
fluence this decision in any way. However, this will be an
outcome and the case will still be analyzed as CLOSED
in the primary intention to treat analysis. The timing of
re-operation for an OPEN abdomen will be at the
discretion of the treating physicians and not dictated by
this trial although the planned secondary determinations
of bio-mediator profiles will be analyzed on a
per-protocol basis only for patients that had at least 24 h
of continuous OPEN or CLOSED management as
allocated.
Outcomes
The primary outcome will be survival at 90 days.
Secondary outcomes will be considered logistical,
physiologic, as well as outcomes that will enable an eco-
nomic analysis (a measure of utility and health-care
costs). Logistical outcomes will include days free of
(DFO) ICU, ventilation, renal replacement therapy, and
hospital at 30 days from the index laparotomy. The
physiological secondary outcomes will include change in
APACHE II, SOFA, and ARDS scores after laparotomy.
The COOL study inclusion criteria concerning
intra-peritoneal contamination will be recorded, and the
index source control laparotomy and every subsequent
laparotomy will be graded according to the OA
classification system from 2013 World Society of Ab-
dominal Compartment Syndrome (WSACS) grading
scale for OA [24, 56, 57]. Surgical complications occur-
ring after the index laparotomy will be graded according
to Clavien-Dindo (grade I = any deviation from normal
postoperative course, including wound infections opened
at the bedside but not treated with antibiotics; grade II
= requiring pharmacological treatment, e.g., antibiotic
treatment, blood transfusion, or parenteral nutrition;
grade IIIa = requiring surgical, endoscopic, or radiologic
intervention without general anesthesia and grade IIIb =
under general anesthesia; grade IVa = life-threatening
complication requiring IC/ICU management with single
organ dysfunction and grade IVb = with multiorgan dys-
function; grade V = death of patient) [58, 59].
Bio-mediator outcomes for centers participating in
COOL-Max will consist of the measurement of IL-6 and
10, procalcitonin, activated protein C (APC), high-mobility
group box protein 1, C3a, C5a, and mitochondrial
DNA. To enable a full economic analysis, we will
measure 1-year health-care costs using administrative
data and assess overall quality of life at 90 days and
1 year using the Euroqol EQ-5D standardized survey
with translations into participants first language where
necessary. An overview of the study outcomes is pre-
sented in Table 2.
COOL: COOL-Lite, COOL-Max, COOL-Mic, COOL-Cells, and
COOL-Costs
The study will be powered to detect a mortality differ-
ence between the two allocated therapies which will be
the most valuable deliverable of the study. Thus, any
dedicated site can participate if they are committed to
recruit and randomize patients with SCIAS fulfilling the
eligibility criteria during source control laparotomies.
Contributing towards this main outcome will require
only collection of the clinical outcome data and is
known as “COOL-Lite” participation in the study. Inter-
ested sites that have the capability to collect and store
biological samples however will also be encouraged to
participate in the “COOL-Max,” in which samples of
both serum and peritoneal fluid will be collected to
understand the evolution of bio-mediators in the course
of SCIAS and to determine differential effects of open or
closed abdominal therapy on these profiles. Participation
in COOL-Max will involve collection of bio-mediator
samples for a prior analysis as stipulated in Table 3. Par-
ticipating in the COOL-Max effort will however equate
to the collection of serum and peritoneal fluid which will
be stored in a frozen state permitting other secondary
and tertiary analyses correlated to COOL clinical out-
comes in response to questions and avenues for scien-
tific exploration as a result of this study. Other
concurrent science that may be conducted in accordance
Kirkpatrick et al. World Journal of Emergency Surgery  (2018) 13:26 Page 7 of 16
with the main COOL trial will a COOL microbiology
(COOL-Mic) arm that will consider the microbiology of
secondary peritonitis in the OA arm of COOL-Lite and
to follow the subsequent modifications in microbiologic
flora including patients in the CLOSED arm who require
reoperation; an analysis of the behavior of innate
intra-peritoneal cellular defense mechanisms will be
undertaken (COOL-Cells). Analysis of bio-mediator pro-
file kinetics/dynamics will be on a “per-protocol basis”
with per-protocol compliance requiring the delivery of at
least 24 h of allocated treatment before any potential
cross-over occurred regarding CLOSED or OPEN
allocation.
For those patients recruited in Calgary (and potentially
other geographically close sites in Alberta), mass cytom-
etry specimens will be collected from the peritoneal fluid
when possible (COOL-Cells). Mass cytometry is a mass
spectrometry technique based on inductively coupled
plasma mass spectrometry and time of flight mass spec-
trometry used for the determination of the properties of
cells (cytometry). In this approach, antibodies are
conjugated with isotopically pure elements, and these
antibodies are used to label cellular proteins. Cells are
nebulized and sent through an argon plasma, which ion-
izes the metal-conjugated antibodies. The metal signals
are then analyzed by a time-of-flight mass spectrometer.
The approach overcomes limitations of spectral overlap
in flow cytometry by utilizing discrete isotopes as a re-
porter system instead of traditional fluorophores which
have broad emission spectra. These sub-studies are not
the focus of the present document, and COOL itself will
be powered for survival considering the basic
COOL-Lite protocol.
Finally, in COOL-Costs, we will use information on
survival (which can be extrapolated to life expectancy),
quality of life, and health-care costs to conduct a full
economic evaluation. Overall quality of life will be
assessed using the SF-36 and Euroqol EQ-5D-5L at
90 days and 1 year post-enrollment in survivors, either
by paper or by phone, which has been used extensively
in ICU survivors. The potential resource implications of
the intervention include the cost of the strategy itself
(which will be assessed using a microcosting approach)
and include any implications on surgeries performed,
ICU and hospital stay, any costs associated with adverse
events of the treatment strategy, the costs associated
Table 2 Overview of study outcomes
Indicator Timeline
Primary outcome Mortality 90 days
Secondary outcomes
Logistical Days free of ICU 30 days
Days free of ventilation 30 days
Days free of RRTa 30 days
Days free of hospital 30 days
Physiological APACHE IIb scores Up to 30 daysc
SOFAd scores Up to 30 daysc
Pa02/Fi02
e ratios Up to 30 daysc
ARDSf scores Up to 30 daysc
Safety Enterocutaneous fistula 30 days
ACSg and/or severe IAHh 30 days
Intra-abdominal abscess 30 days
Biological Il-6 Up to 30 daysi
IL-10 Up to 30 daysi
Procalcitonin Up to 30 daysi
Activated protein C Up to 30 daysi
High mobility group
box protein 1
Up to 30 daysi
Mitochondrial DNA Up to 30 daysi
C3a and C5a Up to 30 daysi
Microbiological Intra-abdominal Up to 30 daysj
Microbiological cultures
Mass cytometry Intra-peritoneal
inflammatory cells
Up to 30 daysk
Economic Micro-costed resource
consumption
1 year
Quality of life Euroqol EQ-5D-5L 90 days and 1 year
SF-36 90 days and 1 year
aRRT renal replacement therapy
bAcute Physiology and Chronic Health Evaluation Score
cMeasured daily using the worst value of that day
dSOFA Sequential Organ Failure Assessment
ePa02/Fi02 partial pressure of oxygen over inspired fraction of oxygen
fARDS Acute Respiratory Distress Syndrome
gACS Abdominal Compartment Syndrome
hIAH intraabdominal hypertension
iMeasured as per Table 3
jMeasured as clinically indicated by the treating team
kMeasured on intra-peritoneal fluid obtained in Calgary
Table 3 Summarized bio-mediator samples for COOL-MAX centers
Will be drawn from both the serum and peritoneal fluid
Timing of sample collection
- Enrollment in the OR
- 6 h post enrollment
- 12 h post enrollment
- 18 h post enrollment
- 24 h post enrollment
- 36 h post enrollment
- 48 h post enrollment
- 72 h post enrollment
- 168 h (7 days) post enrollment
- 336 h (14 days) post enrollment
- 720 h (30 days) post enrollment
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with renal replacement therapy use after ICU discharge,
and subsequent hospital readmissions. To measure these
impacts, we will assess hospital and ICU length of stay,
the number of surgeries performed (and types), physician
interactions, and subsequent use of RRT for all patients
within the trial, with valuation of all costs being based on
all patients enrolled within Alberta, and other participat-
ing sites able to provide administrative and microcosting
data. Microcosting data is available for all hospitalizations
within sites in Alberta, which will enable an accurate
evaluation of ICU costs separate from hospital ward
costs—critical to this analysis. Additional health adminis-
trative data is also available in Alberta, including the abil-
ity to track all physician claims, and subsequent long-term
dialysis use for study participants, using methods familiar
to study investigators. For secondary analyses to inform
policy makers in other countries, we will obtain similar
costing information from additional participating coun-
tries to evaluate the cost-effectiveness in varying economic
contexts and enable the broadest possible generalizability
and policy relevance of our analysis.
Participating centers
Participating institutions will be expected to be familiar
with the proper utilization of the ANPPT device or else
undergo an in service with a content matter expert on
ANPTT device utilization prior to site participation. For
both arms of the trial, it will be expected that attending
surgeons are involved in either the direct supervision and/
or inter-operative participation with either facial closure
or temporary abdominal closure in order to be an accept-
able participating center. Further criteria required for po-
tential participating centers are presented in Table 4.
Sample size calculations
The COOL trial will overall be powered to detect a sig-
nificant difference in the primary outcome, 90-day sur-
vival. While there is little solid data with which to
integrate, the preceding peritoneal VAC study revealed
an intention-to-treat 90-day mortality of 21.7% in the
ABThera group versus 50.0% in the Barker’s vacuum
pack group [HR, 0.32; 95% confidence interval (CI),
0.11–0.93; P = 0.04] [60]. This 30% reduction in mortal-
ity is likely too dramatic to expect to be practically repli-
cated, and thus, a more conservative effective of 10%
reduction in mortality would be appropriate. Thus, given
a mortality rate of 33% in the general population of
those with severe intra-abdominal sepsis, and consider-
ing a power of 80% and an alpha of 0.05, the number
needed to recruit in each arm is 275 patients.
Statistical analyses
The effectiveness of randomization will be displayed
through a detailed presentation of patient demographic
characteristics as outlined in Table 5. The analysis of the
primary outcome, mortality, will be on an intention-to-treat
basis related to the allocation of initial intra-operative ther-
apy. There will be a planned subgroup analysis of the
actuarial mortality stratifying patients into those with and
without the presence of septic shock (defined as Sepsis-3
Consensus Guidelines) during the first 48 h after onset of
peritonitis (if known and 24 h before and 24 h after the first
laparotomy if not known). Secondary outcomes are
described in Table 2. For the comparison of health-care
costs, we will use established methods to enable compari-
sons of mean costs, as these are easily interpretable and
relevant to health-care payer. We will include the full cost of
the intervention, as well as the hospital costs for the cost
categories noted above (for both groups) and will use
non-parametric bootstrap estimates to derive 95% confidence
Table 4 Site requirements for potential participation in the
COOL study
Minimal system resources required for site participation in COOL-Lite
- Designated primary investigator presumably with an academic
affiliation willing to take overall medical/ethical/academic
responsibility for the conduct of the study
- Ethical approval—by the appropriate local ethics committee with
oversight of the participating institution
- Site investigators/willing local surgeons with the responsibility of
caring for those with SIAS and thus the ability to recruit patients
- Internet access—either within or closely available to the operating
theater to allow online randomization of patients during laparotomy
- Negative peritoneal pressure therapy (NPPT) dressing availability for
those randomized to OPEN
- Familiarity with the application of the NPPT device or willingness to
undergo training and in service on the safe utilization of the NPPT
device
- Study personnel/investigator capable to record and compile case
record and submit to the Central Study Registry
Full system resources required for site participation in COOL-Max
- Above and also
- Study personnel capable of obtaining blood/IPF samples
- Laboratory capability to store frozen blood/IPF fluid till study
completion and send to Calgary for analysis
Full system resources required for site participation in COOL-Mic
- Medical microbiology laboratory capable of basic microbiology studies
- Medical records and information processing capable of providing
microbiology results for study analysis
Full system resources required for site participation in COOL-Cells
- Geographic proximity to Calgary
- Ability to collect fresh peritoneal fluid and to rapidly ship to the
Snyder laboratory for time-of-flight mass spectrometer
Full system resources required for site participation in COOL-Costs
- Ability to provide administrative and microcosting data
- Ability to administrator SF-36 and Euroqol EQ-5D-5L at 90 days and
1 year post enrollment in all survivors
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interval (95% CI) and mean cost differences between the
treatment arms. We will use 1000 bias-corrected bootstrap
replications (including sampling with replacement from the
original data) to estimate the distribution of a sampling
statistic to derive 95% confidence intervals. In sensitivity
analyses, we will also use generalized linear models to com-
pare total costs across groups, considering three family distri-
butions (Gaussian, inverse Gaussian, and gamma) and
specifying two link functions (identity and log).
There will be a single interim analysis planned after
the recruitment of 275 patients, which will analyze the
difference in 90-day mortality between allocated therap-
ies. The COOL investigators appreciate the general
reluctance to stop randomized trials early due to the
benefit and due to the frequent over-estimating of
treatment effects [61–63]. Despite this, it is possible that
the COOL trial will be great over-powered as although
the sample size calculations are based on the best out-
come data from randomized trials of NPPT, this is still
inferential as there is no previous relevant data with
which to accurately guide such calculations. Thus, if a
profoundly significant difference is found (p < 0.01), the
trial will be stopped; otherwise, it will continue to full
recruitment (Fig. 2).
Ethical concerns
The Hippocratic Oath requires physicians to “consider
for the benefit of my patients and abstain from whatever
is deleterious and mischievous” and to “give no deadly
medicine to any one if asked, nor suggest any such
counsel”. Thus philosophically, as there is complete clin-
ical equipoise concerning the treatment of SCIAS with
or without the OA technique, the COOL investigators
feel a moral imperative to provide the best evidence to
counsel bedside critical care physicians and surgeons
[64]. The COOL trial is currently approved by the Con-
joint Research Ethics Board of the University of Calgary
(REB-16-1588) to proceed with a delayed consent
process given the time-sensitive critical nature of deci-
sion making. Research ethics will vary throughout the
world, and it is anticipated that various local policies
concerning community consent, waiver of consent, or
informed consent of significant patient proxies will vary
among the local approaches to ensure the COOL trial is
performed to the highest ethical standards on a global
basis. All participating institutions will thus be required
to obtain ethical approval appropriate and applicable to
their institutions.
Discussion
The COOL trial has been designed to answer a critical
clinical question that faces clinicians worldwide on a
daily basis for which there is great clinical equipoise and
potential severe consequences for patients in regard to
potential poor outcomes [30, 42]. Thus, this question
has been identified as one requiring urgent study by the
most contemporary of international reviews [52]. Subse-
quently, the COOL trial has been endorsed by numerous
Table 5 Baseline demographic characteristics of the study patients
Male/female,
Age, median (IQRa), years
Septic shockb
World Society of Emergency Surgery Sepsis Severity Scorec
Calgary PIRO Scored
GCSe, median (IQR)
APACHE IIf, median (IQR)
Arterial pH, mean (95% CI)
Base deficit, median (IQR)
Lactate, median (IQR)
INRg, median (IQR)
Temperature, mean (95% CI)
APACHE-II scoref, mean ± SDd
SOFA scoreh, mean ± SDe
Charlson Comorbidity Index scorei, median (IQR)
Worst physiologic measurements prior to randomization, median (IQR)
Systolic blood pressure, mmHg
Temperature (injured patients), °C
Temperature (sepsis patients), °C
pH
Lactate, mmol/L
Base deficit, mmol/L
INR
Fluid administration prior to randomization, median (IQR)
PRBCj, units
FFPk, units
PRBC/FFP ratio
Crystalloid, L
Patient location prior to OR admission—no. (%)
Emergency department
Hospital ward
Intensive care unit
Vasopressors required prior to randomization—no. (%)
Hours from sepsis diagnosis to laparotomy, median (IQR)
aIQR interquartile range
bSeptic shock as defined by SESPS-3 guidelines [7]
cWSESSS [8]
dCPIRO [43]
eGCS Glasgow Coma Score
fAcute Physiology And Chronic Health Evaluation II
gINR international normalized ratio
hSOFA Sequential Assessment of Organ Failure [110]
iCharlson Comorbidity Index [111]
jPRBC packed red blood cells
kFFP fresh frozen plasma
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scientific organizations with vested interest in the best
care of the critically ill patient including the Abdominal
Compartment Society, the World Society of Emergency
Surgery, the Trauma Association of Canada, the Canadian
Association of General Surgeons, and the Canadian
Hernia Society. The trial design and vision follow directly
from the preceding single-center study of differing modal-
ities of APNPPT conducted at the Foothills Medical
Centre, which noted a survival advantage associated with
a more efficient APNPPT without being able to confirm a
biological mechanism of such [41, 60]. When the periton-
eal VAC investigators considered following up the pilot
study and enrolling more patients in a multi-center fash-
ion, it became apparent that any differing effectiveness of
ANPPT techniques was not the most relevant question
concerning the OA. With a dramatic evolution in resusci-
tation practices involving balanced resuscitation practices,
more and more trauma patients who previously become
so edematous required OA therapy, are no longer being
crystalloid over-resuscitated, and can thus be primarily
closed [65–67]. This dramatic change in the trauma care
paradigm has justified questions regarding the whole
premise of Damage Control Surgery for trauma [68] and
justifies the randomized control trial of the practice in
trauma patients [69].
As over-resuscitation becomes rare, and de-resuscitation
becomes a focus [70], it is intuitive that there will be more
abdomens in non-trauma intra-abdominal sepsis patients
who may be technically closed without inducing
intra-abdominal hypertension (IAH). However, although
these abdomens may be closed, should they be closed? As
has been recently emphasized, there are profound
differences in the basic science of sepsis and traumatic in-
jury [71], with the previously unifying concepts of
non-infectious Systemic Inflammatory Response Syndrome
(SIRS) being effectively discarded as a clinically helpful con-
struct [7, 72, 73]. The one nebulous, poorly defined “holy-g-
rail” of the optimal management of SCIAS is adequate
“source control.” It is suggested that even if an abdomen
can be physically closed, there may be an advantage to
leaving it open to allow better drainage of intra-peritoneal
contamination, a concept that is supported by remarkable
animal lab data suggesting the ability of ANPPT to mitigate
the elaboration of the inflammatory bio-mediator cascade
[39, 40, 74]. Coupled with technical advances in ANPPT
dressings that are safer to utilize and that increasingly pro-
tect the viscera, this appears an attractive option for the
sickest IAS patients.
The peritoneal cavity as a reservoir for systemic
inflammation
There is a complex relationship between pressure, ische-
mia, and inflammation within the peritoneal cavity [10]. In-
dependently, the damaged gut seems to act as a continued
source of inflammation propagating SIRS and potentiating
MODS [75–77]. Although extremely complicated, visceral
ischemia further characteristically generates multiple im-
munological mediators with the pro-inflammatory cyto-
kines tumor necrosis factor-alpha (TNF-α), and interleukin
6 (IL-6), as well as inhibitive cytokines such as interleukin
10 (IL-10) [78–81]. Post-operative complications are as-
sociated with increasing levels of systemic IL-6 and
peritoneal TNF-α [80, 82]. Jansson and colleagues be-
lieve that peritoneal cytokines in humans respond
more extensively compared to systemic cytokine and
that a normal postoperative course is characterized by
decreasing levels of peritoneal cytokines based on
studies of both elective and emergency surgery [83].
Overall, the peritoneal cytokine response is much
higher than the systemic response in peritonitis [81,
Fig. 2 Participant time line for COOL recruitment
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84–86]. Hendriks demonstrated that peritoneal cyto-
kine levels (especially IL-6, TNF-α [87], and IL-10)
were dramatically different in rats who either survived
or succumbed to an intra-peritoneal sepsis model in
the 24 h after cytokine determination [84]. Finally,
the recent work suggests that blood filters designed
to hemofiltrate blood endotoxins and cytokines may
improve hemodynamics, organ dysfunction, and even
mortality in the critically ill [88–91].
We believe that if it can be done safely, it is logical to
attempt to remove intra-peritoneal bio-mediators to po-
tentially ameliorate the local effects and to prevent them
being absorbed systematically. Although early uncon-
trolled work suggested benefit to simple continuous
peritoneal lavage after either gross peritoneal contamin-
ation in secondary peritonitis or in the setting of necro-
tizing pancreatitis [92, 93], more structured studies
could not confirm such benefits [94–96]. Thereafter,
work focused upon using hemofiltration to remove in-
flammatory mediators from the blood which has been
associated with reduced elevations of inflammatory
cytokines (as assessed by blood IL-6 levels), early im-
provements of hemodynamic state, and decreased lactate
levels [97–99]. In an attempt to comprehensively
increase efficiency, the potential utility of adding
extra-corporeal mediator removal through hemofiltra-
tion in addition to continuous peritoneal lavage have
been entertained and studied in early models [91].
ANNPT therapy may be a more direct and focused so-
lution to this complicated problem and one that will be
complementary to the other benefits of OA use in the
sickest patients. Whether improved post-operative
courses can be obtained through this relatively simpler
approach of actively removing peritoneal cytokines with
a more efficient and comprehensive VAC therapy in
humans is therefore a stated secondary but important
objective of the COOL-MAX arm of this trial.
Another potential benefit of ANPTT after severe infec-
tion may be the attendant decompression of the abdom-
inal compartment and prevention of even modest
degrees of IAH. Patients with intra-abdominal infections
are at risk of elevated IAP both as a result of the primary
intra-peritoneal disease, as any large fluid resuscitation
often required to maintain organ perfusion [100–102].
Recent studies have demonstrated a high prevalence of
IAH following aggressive resuscitation of septic pa-
tients. Intra-abdominal hypertension is present in as
many as 80% of septic medical and surgical ICU patients
[103, 104]. Reintam also reported that septic patients with
IAH had a 50% rate of mortality compared to 19% without
IAH, making IAH a significant marker for an increased
risk of death [105]. Within our own institution, rates of
IAH were over 87% of septic ICU patients, and further
61% of these patients had severe IAH at levels
commensurate with ACS, despite the fact that IAP was
only measured in 10% of the patients in whom guidelines
recommend monitoring [106]. Although direct translation
to humans is uncertain, even modest degrees of IAH
(often clinically ignored) have been found to have pro-
found far-reaching effects on propagating multiple organ
failure in animals with ischemia/intra-peritoneal infections
[107–109].
The investigators and the scientific community have
extensively reviewed and critiqued the results of the pre-
ceding peritoneal VAC trial [90]. Methodologic concerns
with the peritoneal VAC trial were that it enrolled quite
heterogeneous patients with a wide range of ages and in-
cluded traumatized patients with an exactly known time
of injury and severe IAS patients in whom the timing of
onset of severe disease was inexactly known. Thus, the
COOL trial will focus on a less heterogeneous group of
patients with intra-operatively confirmed SIAS in order
to increase the signal to noise ratio. The Steering Group
considers conducting the COOL trial to be a practical
undertaking. With a projected total necessary recruit-
ment of 550 patients and with an average institutional
estimate of 10 such patients recruited per year, this pro-
jects to 28 actively engaged centers globally for 2 years.
The initial expressed interest far exceeds this number of
centers, and it is likely that many will be able to recruit
many more than 10 per year. For example, at the Pilot
Center, Foothills Hospital in Calgary, Canada, the group
was extremely supportive with the similar recruitment
process of the peritoneal VAC trial, in which out of 63
potentially eligible patients, 45 (71%) were recruited over
15 months [27], with reasons for non-recruitment in-
cluding gynecological procedures and rescue laparoto-
mies outside of a regular operating room.
Conclusions
The COOL trial will be powered on demonstrating a mor-
tality difference in this highly lethal and morbid condition
to ensure critically ill patients are receiving the best care
possible and not being harmed by inappropriate therapies
based on opinion only. As this will constitute a major
international collaborative, undertaking a number of sec-
ondary outcomes will be conducted that are expected to
add to the basic and translational science of SCIAS.
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